Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the results of meta-analysis suggested that the NQO1 C609T polymorphism is a risk factor for DT cancers, including GC and CRC.
|
29652514 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Consistent with this pro-tumorigenic function for NQO1, high NQO1 expression levels correlate with increased HIF-1α expression and poor colorectal cancer patient survival.
|
27966538 |
2016 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The NQO1*2 T allele of SNP rs1800566 was found associated with an increased risk for proximal colorectal cancer, whereas SNP rs1131341 was rare in our Dutch population and was not associated with GI cancer.
|
24830960 |
2014 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that there is an obvious association between NQO1 Pro187Ser polymorphism and colorectal cancer risk in Asians.
|
24142528 |
2014 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the meta-analysis provides strong evidence for the association between NQO1 C609T polymorphism and colorectal cancer risk, and the T allele of NQO1 C609T polymorphism is an important risk factor of colorectal cancer.
|
23893397 |
2013 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the NQO1 609C>T polymorphism plays an important role in the development of colorectal cancer in the Chinese population, which is strengthened by alcohol drinking or tobacco smoking.
|
23458878 |
2013 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis provided evidence that NQO1 rs1800566 genetic polymorphism was associated with increased risk of colorectal cancer and that the T allele probably acts as an important risk factor.
|
22215148 |
2012 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, NQO1 Pro187Ser was not associated with risk of colorectal cancer, without between-study heterogeneity.
|
22306249 |
2012 |
Colorectal Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We used colorectal cancer (CRC) cell lines and surgical specimens to investigate the methylation status of the KEAP1 promoter region as well as expression of Nrf2 and its downstream antioxidative stress genes, NQO-1 and AKR1C1.
|
22325485 |
2012 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
We here carried out a case-control study and examined the genotype distribution of NQO1 C609T (Pro189Ser) using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach, to investigate the possible role of this SNP as a risk factor in colorectal cancer development in Kasmir, India.
|
20593958 |
2010 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population.
|
20593958 |
2010 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Calculation of crude Odds Ratios (ORs) revealed an increased risk for CRC associated with variant NQO1 (OR 1.5, 95% CI 1.1-2.0) and CYP2E1 intron 6 genotypes (OR 2.2, 95% CI 1.3-3.8).
|
16039674 |
2006 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Results from our meta-analyses suggest that the variant NQO1 Pro187Ser genotype may affect individual susceptibility to lung, bladder, and colorectal cancer.
|
16702380 |
2006 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Correlative polymorphism of NAD(P)H: quinone oxidoreductase (NQO1) with telomere shortening in colorectal cancer.
|
12529991 |
2003 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer.
|
10663383 |
2000 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetically determined variations in NQO1 may modify the risk for CRC and these risks may be greatest for tumors containing K-ras codon 12 mutations.
|
11023538 |
2000 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phase 1 clinical evaluation of oltipraz has demonstrated its ability to induce GST activity as well as the level of transcripts encoding gamma-glutamylcysteine synthetase (gamma-GCS) and DT-diaphorase in the colon mucosa of individuals at increased risk for colorectal cancer.
|
9679568 |
1998 |